Ascentage Pharma Group International
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AAPG research report →
About the company
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation.
- CEO
- Dajun Yang
- IPO
- 2025
- Employees
- 567
- HQ
- Suzhou, CN
Price Chart
- Market Cap
- $1.72B
- P/E
- -9.42
- P/S
- 20.51
- P/B
- 8.75
- EV/EBITDA
- -10.02
- Div Yield
- 0.00%
- Gross Margin
- 84.09%
- Op Margin
- -210.42%
- Net Margin
- -216.74%
- ROE
- -123.61%
- ROIC
- -33.71%
- Revenue
- $558.48M · -43.05%
- Net Income
- $-1,208,909,966 · -198.18%
- EPS
- $-13.56 · -152.99%
- Op Income
- $-1,179,161,166
- FCF YoY
- -785.91%
- 52W High
- $48.45
- 52W Low
- $16.36
- 50D MA
- $19.62
- 200D MA
- $26.83
- Beta
- 0.66
- Avg Volume
- 10.34K
Get TickerSpark's AI analysis on AAPG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Miyara Faical | other | 0 |
| May 21, 26 | Zhai Yifan | other | 95,575 |
| May 21, 26 | Zhai Yifan | other | 92,746 |
| May 20, 26 | Zhai Yifan | other | 298,195 |
| May 20, 26 | Zhai Yifan | other | 298,194 |
| May 20, 26 | Zhai Yifan | other | 214,999 |
| May 20, 26 | Zhai Yifan | other | 214,988 |
| May 20, 26 | Zhai Yifan | other | 103,365 |
| May 20, 26 | Zhai Yifan | other | 103,364 |
| May 20, 26 | Zhai Yifan | other | 95,575 |
Our AAPG coverage
Recent articles, reports, and earnings notes.
No research on AAPG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AAPG report →Similar companies
Peers in the same neighborhood.